EMA Authorised: Iclusig (ponatinib) — Incyte Biosciences Distribution B.V.

View source ↗

Summary

The EMA authorizes Iclusig (ponatinib) for leukemia indications under accelerated assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia Lymphoid
• Leukemia Myeloid

Drugs mentioned

• Iclusig (ponatinib)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myeloid;Leukemia, Lymphoid. MAH: Incyte Biosciences Distribution B.V.. Decision date: 15/07/2026. Accelerated assessment